论文部分内容阅读
甲氟喹是一对人类各种疟原虫感染安全有效的药物,但疟原虫对其抗药性发展的危险必须予以重视。本文作者比较了用750mg或1250mg甲氟喹一次口服治疗泰国恶性疟患者时的药代动力学和药效学。20名志愿受试者系急性恶性疟男性患者,年龄16～42岁,体重45～60kg,无肝肾病史,病人在研究过程中仅服用甲氟喹。患者被随机分为2组,分别一次口服750mg或1250mg甲氟喹,并于服药后0,0.5,1,1.5,2,2.5,3,4,5,6,8,10,12,14,18,24,28和36h及2,3,4,5,7,14,21,28,35和42天各
Mefloquine is a safe and effective drug against a variety of human infections of Plasmodium, but the risk of Plasmodium resistance to its development must be addressed. The authors compared the pharmacokinetics and pharmacodynamics of a once-a-day oral treatment of thallus falciparum malaria with either 750 mg or 1250 mg of mefloquine. Twenty volunteers were male patients with acute falciparum malaria, aged 16-42 years and weighing 45-60 kg, without a history of liver and kidney disease. Patients were treated with mefloquine only during the study. Patients were randomly divided into two groups, respectively, once oral 750mg or 1250mg mefloquine, and after taking 0,0.5,1,1.5,2,2.5,3,4,5,6,8,10,12,14, 18, 24, 28 and 36h and 2, 3, 4, 5, 7, 14, 21, 28, 35 and 42 days each